In a report released today, Brooks O’Neil from Lake Street maintained a Buy rating on Augmedix (AUGX – Research Report), with a price target of $8.00. The company’s shares closed yesterday at $5.72.
O’Neil covers the Healthcare sector, focusing on stocks such as Alphatec Holdings, Augmedix, and ModivCare. According to TipRanks, O’Neil has an average return of 0.4% and a 49.20% success rate on recommended stocks.
Currently, the analyst consensus on Augmedix is a Strong Buy with an average price target of $7.38.
See Insiders’ Hot Stocks on TipRanks >>
Based on Augmedix’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $11.77 million and a GAAP net loss of $4.41 million. In comparison, last year the company earned a revenue of $7.86 million and had a GAAP net loss of $5.49 million
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AUGX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Augmedix (AUGX) Company Description:
Augmedix Inc humanizes the clinician-patient experience by enabling clinicians to focus on what matters most, delivering high-quality patient care. It converts natural clinician-patient conversation into medical documentation and provides real-time administrative support, including referrals, orders, and reminders. The service, which supports over 35 specialties, delivers timely, accurate and comprehensive medical documentation to several of the healthcare systems in the U.S. and to hundreds of independent clinicians nationwide. Augmedix focuses on saving clinicians 2-3 hours per day, improve clinician productivity by as much as 20%, and increase clinicians’ satisfaction with work-life balance over 40%.
Read More on AUGX:
- Augmedix Exits Calendar 2023 with Expected $51 Million in Annual Recurring Revenue
- Augmedix initiated with neutral view at Evercore ISI, here’s why
- Augmedix initiated with an In Line at Evercore ISI
- Augmedix Partners with Google Cloud to Bring Medically-Tuned AI Technology to Ambient Documentation
- Augmedix management to meet with Lake Street
